Clinical Trial

Neurophet Showcases ‘Brain Imaging AI Solutions’ at BIO USA, Accelerates Global Business Development Collaborations

Introduces key products including an integrated brain imaging analysis solution for Alzheimer's disease treatment decision-makingExpands partnering efforts with global pharmaceutical...

Matica Biotechnology and Cirsium Biosciences Announce Adoption of Matica Open Access Platform to Accelerate Flexible AAV Manufacturing

Collaboration highlights open-access model enabling speed, flexibility, and freedom fromtraditional CDMO constraintsCOLLEGE STATION, Texas and SAN DIEGO, June 16, 2026...

Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

Accepted abstracts showcase Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and...

Faculty Introduces the Frontier Life Sciences Developer Studio, Giving Clinical Trial Teams a Faster Path to Simulation-Driven Decision Intelligence

The latest release for Faculty Frontier™ introduces an enhanced development environment for life sciences decision engineers to build, validate, and...

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola – NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating...

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time...

Sparrow Pharmaceuticals Announces Interim CAPTAIN-T2D Data Validating High Prevalence of Elevated Cortisol in Difficult-to-Control Type 2 Diabetes

More than 75% of patients screened show elevated cortisol level associated with increased prevalence of cardiovascular disease Inadequate glycemic control...

error: Content is protected !!